Cardiol Therapeutics EBIT

The latest EBIT for CRDL is $-37M as of June 2026. That compares with $-40M in the prior-year period — up 8.9% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Cardiol Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CRDL's EBIT moved from $-40M to $-37M — a 8.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cardiol Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, CRDL currently prints $-37M for EBIT, while the sector average sits near $23B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at Cardiol Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-37M for CRDL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting CRDL's EBIT ($-37M), review year-over-year change from $-40M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.